On February 19, 2025 Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I), reported a licensing agreement with the University of Alabama at Birmingham (UAB) to support their research in B cell development (Press release, Nona Biosciences, FEB 19, 2025, View Source [SID1234650389]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, UAB, represented by Dr. James Kobie, has been granted a non-exclusive license to use Nona’s H2L2 Harbour Mice platform to develop fully human antibodies. This will enable UAB researchers to pursue breakthroughs in B cell development work.

Dr. Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, commented, "Many transformative therapies originate from academic laboratories. We are excited to support UAB’s research efforts. This highlights our commitment to leveraging our antibody discovery technologies to bridge the gap between scientific discovery and real-world therapeutic applications, addressing unmet medical needs and benefiting patients worldwide."

Dr. James Kobie, PhD, Associate Professor in the Division of Infectious Disease at the UAB School of Medicine, said, "We hope — through our research — to address fundamental questions about the human B cell receptor repertoire and develop monoclonal antibodies with therapeutic and diagnostic potential for infectious disease and oncology targets."